Incyte Corp (INCY) R&D head sells 15,888 shares, retains 215,444

Rhea-AI Filing Summary

Incyte Corp executive Pablo J. Cagnoni, President and Global Head of R&D, reported selling 15,888 shares of common stock on 2026-07-31 at $119.70 per share in an open market or private transaction. After the sale, he directly holds 215,444 shares, including 183,200 shares issuable from previously reported restricted stock units and earned performance stock units that have not vested. The transaction was made under a Rule 10b5-1 trading plan.

Insider Trade Summary 10b5-1

Net Seller: 15,888 shares

Net Sell 1 txn

Insider CAGNONI PABLO J

Role President, Global Head of R&D

Sold 15,888 shs ($1.90M)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	15,888	$119.70	$1.90M

Holdings After Transaction: Common Stock — 215,444 shares (Direct)

Footnotes (1)

1. F1. This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.

Key Figures

Shares sold: 15,888 shares Sale price: $119.70 per share Shares held after transaction: 215,444 shares +1 more

4 metrics

Shares sold 15,888 shares Common stock sale reported on 2026-07-31

Sale price $119.70 per share Per-share price for 15,888 shares sold

Shares held after transaction 215,444 shares Direct common stock holdings following the sale

Unvested stock units included 183,200 shares Shares issuable from restricted and performance stock units that have not vested

Key Terms

Rule 10b5-1 trading plan, restricted stock units, performance stock units, vested

4 terms

Rule 10b5-1 trading plan regulatory

"The transaction was made under a Rule 10b5-1 trading plan."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock units financial

"shares of common stock issuable pursuant to previously reported restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

performance stock units financial

"issuable pursuant to previously reported restricted stock units and earned performance stock units"

Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.

vested financial

"earned performance stock units that have not vested"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/04/2026 - 04:05 PM Accepted by SEC EDGAR 08/04/2026 - 04:04 PM Learn about SEC filing dates

FAQ

What insider transaction did INCYTE CORP (INCY) report for Pablo J. Cagnoni?

Pablo J. Cagnoni reported a sale of 15,888 shares of Incyte common stock on 2026-07-31. The transaction was coded as a sale in an open market or private transaction and reported on a Form 4.

At what price were the INCY shares sold by Pablo J. Cagnoni?

The reported sale of Incyte (INCY) shares by Pablo J. Cagnoni was executed at $119.70 per share. This per-share price applies to the 15,888 shares of common stock sold on 2026-07-31.

How many INCYTE CORP (INCY) shares does Pablo J. Cagnoni hold after this Form 4 sale?

Following the reported sale, Pablo J. Cagnoni directly holds 215,444 shares of Incyte common stock. This total includes 183,200 shares issuable under previously reported restricted stock units and earned performance stock units that have not yet vested.

Were Pablo J. Cagnoni’s INCY share sales made under a Rule 10b5-1 trading plan?

Yes. The Form 4 indicates the transactions were conducted under a Rule 10b5-1 trading plan. Such pre-arranged plans allow insiders to sell shares according to preset instructions, independent of subsequent material nonpublic information.

What is Pablo J. Cagnoni’s role at INCYTE CORP (INCY)?

Pablo J. Cagnoni serves as President, Global Head of R&D at Incyte Corp. His Form 4 filing reflects transactions and holdings in the company’s common stock associated with this executive position.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CAGNONI PABLO J

(Last) (First) (Middle)

1801 AUGUSTINE CUT-OFF

(Street)

WILMINGTON DELAWARE 19803

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
INCYTE CORP [ INCY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, Global Head of R&D

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/31/2026		S		15,888	D	$119.7	215,444(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This includes an aggregate of 183,200 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.

Remarks:

	/s/ Elizabeth Feeney, Attorney-In-Fact	08/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)